Advertisement

Treatment of Hepatitis C Virus in Special Populations (HBV Coinfection, Drug Users, and Prisoners)

  • Dalbir S. Sandhu
  • Randhir JesudossEmail author
Chapter

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) share the pathways of transmission and, consequently, dual-HBV/HCV infection is frequently observed in geographical areas where both infections have an intermediate or a high endemicity level and in special populations at high risk of acquiring both infections. Patients with dual-HBV/HCV infection more frequently develop liver cirrhosis and hepatocellular carcinoma (HCC) than those with a single infection. In vitro, morphologic and clinical investigations have shown the reciprocal inhibition of HBV and HCV genomes. The treatment of hepatitis C in these special populations is complex and decision is made on the stage of liver disease, virus predominance, and presence of human immunodeficiency virus (HIV) infection and comorbidities. Treatment with PEG-IFN and ribavirin for HCV eradication has been replaced by a combination of two or more directly acting antivirals (DAAs) of different classes with DAA regimens becoming the therapy of choice in HCV and hence in HBV/HCV dual infection with sustained virological response (SVR)12 rates in the 95% range. Tenofovir or entecavir must be integrated with DAA treatment in patients with both HCV and HBV in a chronic active phase, in those with cirrhosis, and in those coinfected with HIV. Treatment of hepatitis C in IV drug users (IVDU) and prisoners is best served in a multidisciplinary setting. Comparable rates of adherence and reinfection are found in IVDU compared to nondrug users. DAAs in combination with programs such as needle syringe program and opiate substitution therapy will help treat hepatitis C in IVDU and prevent transmission.

Keywords

Hepatitis C Hepatitis B Intravenous drug users Prisoners 

References

  1. 1.
    Sagnelli E, Sagnelli C, Macera M, Pisaturo M, Coppola N. An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother. 2017;18(16):1691–702.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21(42):11931–40.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Crespo J, Lozano JL, de la Cruz F, Rodrigo L, Rodriguez M, San Miguel G, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994;89(8):1147–51.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. Hepatology. 1999;30(1):257–64.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Fattovich G, Tagger A, Brollo L, Giustina G, Pontisso P, Realdi G, et al. Hepatitis C virus infection in chronic hepatitis B virus carriers. J Infect Dis. 1991;163(2):400–2.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Sagnelli E, Coppola N, Messina V, Di Caprio D, Marrocco C, Marotta A, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology. 2002;36(5):1285–91.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Ohkawa K, Hayashi N, Yuki N, Hagiwara H, Kato M, Yamamoto K, et al. Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol. 1994;21(4):509–14.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51(3):759–66.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36(7):2084–6.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Galimany R, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404–10.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Filippini P, Coppola N, Pisapia R, Martini S, Marrocco C, Di Martino F, et al. Virological and clinical aspects of HBV-HCV coinfection in HIV positive patients. J Med Virol. 2007;79(11):1679–85.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Coppola N, Pisapia R, Tonziello G, Martini S, Imparato M, Piai G, et al. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection. Antivir Ther. 2008;13(2):307–18.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Raimondo G, Brunetto MR, Pontisso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43(1):100–7.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992;165(5):831–4.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Alberti A, Pontisso P, Chemello L, Fattovich G, Benvegnu L, Belussi F, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22(1 Suppl):38–41.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Kaklamani E, Trichopoulos D, Tzonou A, Zavitsanos X, Koumantaki Y, Hatzakis A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA. 1991;265(15):1974–6.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75(3):347–54.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Sagnelli E, Pasquale G, Coppola N, Scarano F, Marrocco C, Scolastico C, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection. 2004;32(3):144–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Sagnelli E, Coppola N, Marrocco C, Onofrio M, Sagnelli C, Coviello G, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol. 2006;35(3):317–20.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRefGoogle Scholar
  22. 22.
    AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.CrossRefGoogle Scholar
  23. 23.
    Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–6.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017;32(10):1754–62.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66(1):27–36.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Chen X, Xuan M, Wu D. Study of superinfection of HBV and HCV. Zhonghua Liu Xing Bing Xue Za Zhi. 1999;20(3):141–3.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Xess A, Kumar M, Minz S, Sharma HP, Shahi SK. Prevalence of hepatitis B and hepatitis C virus coinfection in chronic liver disease. Indian J Pathol Microbiol. 2001;44(3):253–5.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Mekky MA, Nasr AM, Saleh MA, Wasif NK, Khalaf M, Aboalam H, et al. Virologic and histologic characterisation of dual hepatitis B and C co-infection in Egyptian patients. Arab J Gastroenterol. 2013;14(4):143–7.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Senturk H, Tahan V, Canbakan B, Dane F, Ulger Y, Ozaras R, et al. Clinicopathologic features of dual chronic hepatitis B and C infection: a comparison with single hepatitis B, C and delta infections. Ann Hepatol. 2008;7(1):52–8.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, et al. Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012;18(14):1616–21.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Dai CY, Yu ML, Chuang WL, Lin ZY, Chen SC, Hsieh MY, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001;16(6):636–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Koike K, Yasuda K, Yotsuyanagi H, Moriya K, Hino K, Kurokawa K, et al. Dominant replication of either virus in dual infection with hepatitis viruses B and C. J Med Virol. 1995;45(2):236–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Semnani S, Roshandel G, Abdolahi N, Besharat S, Keshtkar AA, Joshaghani H, et al. Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol. 2007;18(1):20–1.PubMedGoogle Scholar
  34. 34.
    Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation. 2005;79(9):1132–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538–45.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Sagnelli E, Stroffolini T, Sagnelli C, Smedile A, Morisco F, Furlan C, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: data from a multicenter nationwide survey. Dig Liver Dis. 2016;48(9):1066–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Stroffolini T, Sagnelli E, Gaeta GB, Sagnelli C, Andriulli A, Brancaccio G, et al. Characteristics of liver cirrhosis in Italy: evidence for a decreasing role of HCV aetiology. Eur J Intern Med. 2017;38:68–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Sagnelli E, Stroffolini T, Sagnelli C, Morisco F, Coppola N, Smedile A, et al. Influence of universal HBV vaccination on chronic HBV infection in Italy: results of a cross-sectional multicenter study. J Med Virol. 2017;89(12):2138–43.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999;15(8):699–704.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Reddy GA, Dakshinamurthy KV, Neelaprasad P, Gangadhar T, Lakshmi V. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol. 2005;23(1):41–3.PubMedCrossRefGoogle Scholar
  41. 41.
    Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM, TREAT Asia HIV Observational Database. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol. 2007;22(9):1510–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Rodriguez-Inigo E, Bartolome J, Ortiz-Movilla N, Platero C, Lopez-Alcorocho JM, Pardo M, et al. Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection. J Virol. 2005;79(24):15578–81.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Pasquinelli C, Shoenberger JM, Chung J, Chang KM, Guidotti LG, Selby M, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology. 1997;25(3):719–27.PubMedCrossRefGoogle Scholar
  44. 44.
    Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009;50(1):46–55.PubMedCrossRefGoogle Scholar
  45. 45.
    Zoulim F. Does occult HBV infection have an impact on the evolution of chronic hepatitis C? J Hepatol. 2013;59(4):646–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28(1):27–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002;37(6):855–62.PubMedCrossRefGoogle Scholar
  48. 48.
    Pan Y, Wei W, Kang L, Wang Z, Fang J, Zhu Y, et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem Biophys Res Commun. 2007;359(1):70–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Eyre NS, Phillips RJ, Bowden S, Yip E, Dewar B, Locarnini SA, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol. 2009;51(3):446–57.PubMedCrossRefGoogle Scholar
  50. 50.
    Raimondo G, Saitta C. Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist. J Hepatol. 2008;49(5):677–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105(5):1529–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Nguyen LH, Ko S, Wong SS, Tran PS, Trinh HN, Garcia RT, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011;53(6):1839–45.PubMedCrossRefGoogle Scholar
  53. 53.
    Wiegand SB, Jaroszewicz J, Potthoff A, Honer Zu Siederdissen C, Maasoumy B, Deterding K, et al. Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-gamma-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect. 2015;21(7):710 e1–9.CrossRefGoogle Scholar
  54. 54.
    Sato S, Fujiyama S, Tanaka M, Yamasaki K, Kuramoto I, Kawano S, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol. 1994;21(2):159–66.PubMedCrossRefGoogle Scholar
  55. 55.
    Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol. 2002;37(Suppl 13):65–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19(7):859–68.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Dustin LB, Trehanpati N. Editorial: recent advances in HBV and HCV immunology. Front Immunol. 2015;6:453.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Raimondo G, Rodino G, Smedile V, Brancatelli S, Villari D, Longo G, et al. Hepatitis B virus (HBV) markers and HBV-DNA in serum and liver tissue of patients with acute exacerbation of chronic type B hepatitis. J Hepatol. 1990;10(3):271–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126(4):1024–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Wu JC, Chen CL, Hou MC, Chen TZ, Lee SD, Lo KJ. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology. 1994;19(4):836–40.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology. 1994;107(1):189–95.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut. 1999;45(4):613–7.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver. 1999;19(4):348–53.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol. 2000;95(10):2978–80.PubMedCrossRefGoogle Scholar
  65. 65.
    Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22(4 Pt 1):1101–8.PubMedGoogle Scholar
  66. 66.
    Pontisso P, Gerotto M, Ruvoletto MG, Fattovich G, Chemello L, Tisminetzky S, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol. 1996;48(2):157–60.PubMedCrossRefGoogle Scholar
  67. 67.
    Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology. 1991;14(1):64–7.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341(1):22–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58(3):201–7.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and “silent” HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol. 2001;64(3):350–5.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17(1):20–9.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol. 1998;54(4):249–55.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95(12):3529–36.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology. 1997;44(17):1404–6.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology. 1997;112(1):184–7.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39(1):211–9.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994;74(9):2442–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Chan HLY, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol. 2016;64(5):1011–9.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305(18):1067–73.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Aghemo A, Colombo M. Treatment of patients with dual hepatitis B and C: a step in the right direction. Gut. 2014;63(3):380–1.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2(1):39–45.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–16 e1.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Raedler LA. Viekira pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): All-oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):142–7.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–69.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128(1):176–84.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49(5):688–94.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology. 2018;154(4):989–97.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Potthoff A, Berg T, Wedemeyer H, Group H-NBCCS. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009;44(12):1487–90.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136(2):496–504 e3.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis c virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166(11):792–8.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, et al. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66–70.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202–4.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Available from: http://www.unodc.org
  96. 96.
    Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46(12):1852–8.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Global Burden Of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20–9.CrossRefGoogle Scholar
  99. 99.
    Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI, et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS One. 2013;8(6):e64789.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Linas BP, Hu H, Barter DM, Horberg M. Hepatitis C screening trends in a large integrated health system. Am J Med. 2014;127(5):398–405.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303–13.PubMedCrossRefGoogle Scholar
  103. 103.
    Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329–37.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol. 2013;85(6):1019–27.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Svoboda J, Andreadis C, Downs LH, Miller WT Jr, Tsai DE, Schuster SJ. Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. Leuk Lymphoma. 2005;46(9):1365–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin LYMPHOMA in response to antiviral therapy for hepatitis C virus infection. Intern Med. 2012;51(19):2745–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Øvrehus ALH, Blach S, Christensen PB, Gerstoft J, Weis N, Krarup H, et al. Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years. 50th Annual meeting of the European association for the study of the liver (EASL) 2015; 2015. p. S591.Google Scholar
  110. 110.
    Zahnd C, Luisa P. Salazar-Vizcaya, Dufour JF, Mullhaupt B, Wandeler G, Kouyos R, et al. Impact of deferring HCV treatment on liver-related events in HIV+ patients. n conference on retroviruses and opportunistic infections (CROI) February 23–26 Seattle, WA; 2015. 2015.Google Scholar
  111. 111.
    Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39–45.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-grazoprevir to treat hepatitis C Virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med. 2016;165(9):625–34.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Mathei C, Bourgeois S, Blach S, Brixko C, Mulkay JP, Razavi H, et al. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227–32.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O. Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study. PLoS One. 2016;11(11):e0166451.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80–9.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Grebely J, Matthews GV, Hellard M, Shaw D, van Beek I, Petoumenos K, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol. 2011;55(1):76–85.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Hellard M, Rolls DA, Sacks-Davis R, Robins G, Pattison P, Higgs P, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60(6):1861–70.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician. 2010;81(11):1351–7.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561–73.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907–17.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S. Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS One. 2017;12(6):e0178398.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, et al. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis. 2017;17(1):420.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis. 2013;57(Suppl 2):S90–6.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res. 2002;8(1):45–9.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Sarpel D. Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. 2016. http://www.nataporg/2016/AASLD/AASLD_75htm
  126. 126.
    Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10(2):310–9.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Dore GJ, Altice F, et al. C-EDGE CO-STAR: adherence and drug use in HCV-infected persons on opioid agonist therapy receiving elbasvir/grazoprevir fixed dose combination for 12 weeks. 2015. https://www.eiseverywherecom/file_uploads/3f3623614b2115f0d3cf584977e25537_GregDorepdf
  128. 128.
    Grebely JF, Zeuzem S, et al. On-treatment illicit drug use did not impact treatment outcome during therapy with ledipasvir/sofosbuvir with or without ribavirin in the phase 3 ION-1 Stud. 2016. http://www.nataporg/2016/EASL/EASL_115htm
  129. 129.
    Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e20.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Grebely J, Swan T, Hickman M, Bruneau J, Bruggmann P, Dalgard O, et al. Contradictory advice for people who inject drugs in the 2016 EASL recommendations on treatment of hepatitis C. J Hepatol. 2017;66(5):1101–3.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Litwin AH, Agyemang L, Akiyama MJ, Norton BL, Heo M, Ning Y, et al. The PREVAIL Study: intensive models of HCV care for people who inject drugs. J Hepatol. 2017;66(1):S72.CrossRefGoogle Scholar
  132. 132.
    Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017;47:202–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Morris L, Smirnov A, Kvassay A, Leslie E, Kavanagh R, Alexander N, et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland injectors’ health network. Int J Drug Policy. 2017;47:216–20.PubMedCrossRefGoogle Scholar
  134. 134.
    Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, Cunningham CO, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196–201.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend. 2017;177:214–20.PubMedCrossRefGoogle Scholar
  136. 136.
    Schitz A, Moser S, Marchart K, Haltmayer H, Gschwantler M. Direct Observed therapy of chronic hepatitis C with interferon-free all-oral regimens at a low-threshold drug treatment facility-a new concept for treatment of patients with borderline compliance receiving opioid substitution therapy. Am J Gastroenterol. 2016;111(6):903–5.PubMedCrossRefGoogle Scholar
  137. 137.
    Litwin AH, Agyemang L, Akiyama MJ, et al. High rates of sustained virological response in people who inject drugs treated with all-oral direct acting antiviral regimens. 2016. https://www.eiseverywherecom/file_uploads/ec626d74ab97207d900ddc93eeb18144_166_AlainLitwinpdf
  138. 138.
    Boglione L, Mornese Pinna S, De Nicolo A, Cusato J, Cariti G, Di Perri G, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. J Viral Hepat. 2017;24(10):850–7.PubMedCrossRefGoogle Scholar
  139. 139.
  140. 140.
    Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–88.PubMedCrossRefGoogle Scholar
  141. 141.
    Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction. 2012;107(11):1984–95.PubMedCrossRefGoogle Scholar
  142. 142.
    Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49–57.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015;22(4):399–408.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2013;56(6):806–16.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
  146. 146.
    Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, Kaldor J, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol. 2010;25(2):143–8.PubMedCrossRefPubMedCentralGoogle Scholar
  148. 148.
    Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323–30.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008;62(4):305–13.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Luciani F, Bretana NA, Teutsch S, Amin J, Topp L, Dore GJ, et al. A prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014;109(10):1695–706.PubMedCrossRefGoogle Scholar
  151. 151.
    Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81(1):25–37.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology. 2012;56(4):1252–60.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Mina MM, Herawati L, Butler T, Lloyd A. Hepatitis C in Australian prisons: a national needs assessment. Int J Prison Health. 2016;12(1):3–16.PubMedCrossRefGoogle Scholar
  154. 154.
    Spaulding AS, Kim AY, Harzke AJ, Sullivan JC, Linas BP, Brewer A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013;21(1):27–35.PubMedGoogle Scholar
  155. 155.
    Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust. 2010;192(9):496–500.PubMedGoogle Scholar
  156. 156.
    El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis. 2011;53(2):150–7.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47(7):952–61.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016;23(12):1009–16.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Marco A, Roget M, Cervantes M, Forne M, Planella R, Miquel M, et al. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018.  https://doi.org/10.1111/jvh.12940.PubMedCrossRefGoogle Scholar
  160. 160.
    Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. Demonstration of near-elimination of hepatitis C Virus among a prison population: the lotus glen correctional centre hepatitis C treatment project. Clin Infect Dis. 2018;67(3):460–3.PubMedCrossRefGoogle Scholar
  161. 161.
    Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546–53.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyCase Western Reserve University/MetroHealth Medical CenterClevelandUSA
  2. 2.Case Western Reserve UniversityClevelandUSA
  3. 3.Internal Medicine/Gastroenterology and HepatologyUniversity of Iowa Hospital and ClinicsIowa CityUSA

Personalised recommendations